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RemyelinationMultiple sclerosis (MS) is characterized by the formation of demyelinating lesions in the white matter (WM).
However, the timecourse of the evolution of healthy white matter into fully demyelinated lesions in MS is not
well understood. We use a recently proposed technique to examine magnetization transfer ratio (MTR)
timecourses in lesions segmented from MTR images in patients with relapsing–remitting MS (RRMS) and sec-
ondary progressive MS (SPMS). In both groups we found MTR lesions forming both in previously normal
appearingWM (de novo lesions) as well as in previously lesional tissue that appears to be experiencing a second
round of inﬂammatory demyelination (repeat lesions). Both de novo and repeat lesions exhibited signiﬁcant, but
incompleteMTR recovery, suggesting partial remyelination; post-lesionMTR values in de novo lesionswere sim-
ilar to pre-lesion values in repeat lesions. Both de novo and repeat lesions were found in subjects in relapsing–
remitting and secondary progressive stages of MS, and repeat lesions appeared relatively more common in the
secondary progressive phase. These observations support the hypothesis that entirely demyelinated lesions
found on histopathology are the result of multiple episodes of demyelination and incomplete remyelination,
and may have implications for MS treatment development efforts aimed at neuroprotection and enhancing
remyelination.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Multiple sclerosis (MS) is an inﬂammatory demyelinating disease of
the central nervous system. The most prominent feature of MS is the
formation of demyelinated lesions in the white matter (WM), which
are associated with a breakdown in the blood–brain barrier (BBB) and
invasion of peripheral immune cells into brain tissue, causing inﬂamma-
tory demyelination. Although very effective remyelination routinely oc-
curs following demyelination associated with traumatic injury (Lasiene
et al., 2008), inmany experimental models of MS, and even inmanyMS
lesions (Fancy et al., 2010; Patrikios et al., 2006; Salgado-Ceballos et al.,
1998), histopathological studies show that remyelination does fre-
quently fail (Patrikios et al., 2006). Lesions with no evidence of
remyelination are typical at autopsy (Miller et al., 1996). Discovering
the reasons for this failure is particularly important as drug discovery ef-
forts have expanded to include neuroprotective and remyelination pro-
moting strategies (Franklin et al., 2002).
Histopathological studies can examine in great detail various aspects
of the inﬂammatory, demyelinating and remyelinating processessridar.narayanan@mcgill.ca
. This is an open access article underoccurring in MS, but can only indirectly examine the dynamic process
of lesion formation and repair. Additionally, tissue available for histo-
pathological investigation is dominated by samples from patients who
have died of either long-standing or particularly aggressiveMS. Because
of this, the detailed timecourse of the evolution of healthy white matter
into fully demyelinated lesions inMS is not well understood. Histopath-
ological studies have provided apparently divergent results (Patrikios
et al., 2006), and some authors have concluded that remyelination is
only transient, with newly remyelinated tissue quickly demyelinating
again (Frohman et al., 2006) or that it fails more frequently in chronic
forms of the disease (Goldschmidt et al., 2009).
One longstanding hypothesis proposes that MS lesions routinely
remyelinate, although not completely, and the fully demyelinated
chronic lesions seen at autopsy are the result of repeated episodes of de-
myelination in the same tissue (Ludwin, 1980). Histopathological ob-
servations of what appear to be demyelinated lesions partially
overlapping shadow plaques (Prineas et al., 1993) provide indirect evi-
dence for this hypothesis. Several studies have induced repeated demy-
elination in predictable locations using animals fed Cuprizone (Johnson
and Ludwin, 1981; Mason et al., 2001) or injection of demyelination-
inducing compounds directly into the brain or spinal cord (Penderis
et al., 2003)with results ranging fromno sign of impaired remyelination
after repeated demyelination (Penderis et al., 2003) to slower, less com-
plete remyelination (Johnson and Ludwin, 1981).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(MRI) and serialMRI studies can provide information about the dynam-
ic nature of MS lesion formation.While conventional MRI is not myelin-
speciﬁc, severalMRI techniques have emerged that may provide amore
direct means of investigating demyelination, remyelination and lesion
development over time. Myelin water fraction (MWF), derived from
multicomponent T2 mapping (Mackay et al., 1994); restricted proton
pool size, derived from quantitative magnetization transfer (qMT) im-
aging (Sled and Pike, 2001); and magnetization transfer ratio (MTR)
(Wolff and Balaban, 1989) provide change measures that are sensitive
and reasonably speciﬁc to changes in myelin content in MS white mat-
ter. MTR, in particular, is easy to compute from conventional images ac-
quired with and without a magnetization transfer prepulse, is available
as a stock sequence option on most recent scanners, and is therefore
suitable for use in clinical trials. MTR has been histopathologically vali-
dated as a marker of myelin content in both humans and animals, and
has a speciﬁcity similar to Luxol fast blue (Barkhof et al., 2003; Chen
et al., 2007; Deloire-Grassin et al., 2000; Dousset et al., 1992; Pike
et al., 2000; Schmierer et al., 2004).
Several studies to date have used these imaging techniques to look
for overall abnormalities in the WM (Filippi et al., 2000; Levesque
et al., 2010; Rocca et al., 1999; van Buchem et al., 1999), or within con-
ventional MRI lesion types (Chen et al., 2007, 2008; Richer et al., 2001).
Recentlywe have demonstrated a technique, based onMTR imaging, for
identifying “ΔMTR lesions”: focal areas of signiﬁcant MTR change
(Brown et al., 2012) that are more speciﬁc to changes in myelin than
in lesions on T1-weighted (T1), T2-weighted (T2) or gadolinium
contrast-enhanced (Gd) images and can also identify recurrent demye-
lination. Analysis of the longitudinal changes in MTR within ΔMTR le-
sions is a statistically powerful method for determining differences in
MTR recovery (Brown et al., 2012).
In this study we examined MTR timecourses in ΔMTR lesions that
appeared either in NAWM or in previously T2 hyperintense tissue. T2
hyperintensity (i.e. a T2 lesion) is generally used as a marker of a previ-
ous focal inﬂammatory demyelinating episode in MS. Therefore, while
ΔMTR lesions arising in NAWM (de novo lesions) might be examples
of initial foci of demyelination, those found in already T2 hyperintense
tissue (repeat lesions) may be subsequent demyelination in tissue
that has already experienced a cycle of demyelination followed
by remyelination. Thus, we investigated the hypothesis that white
matter experiences repeated episodes of focal demyelination and
remyelination.
2. Methods
2.1. Data and processing
Two datasets were used (demographic values are mean ± standard
deviation): (1) a group of 18 relapsing–remitting MS (RRMS) patients
(11 females, age 39 ± 8 years, disease duration 7 ± 9 years) and (2) a
group of 88 subjects with secondary progressive MS (SPMS). Detailed
demographic information was not available for the SPMS group. How-
ever, these were a subset of the group described in Freedman et al.
(2011) (64% females;mean age 50, range 23–72 years; disease duration
9 years); all subjects from imaging sites that had at least one scan of a
normal control, required for MTR normalization, were used.
Subjects in theRRMS groupwere treatedwith teriﬂunomide and im-
aged approximately monthly for 2 years. The SPMS group was scanned
at baseline and at three, six, twelve and eighteen months and treated
with MBP8298. For both groups, image contrasts acquired at each
timepoint included T1, T2 and proton density weighted (PD) scans,
plus images with and without a magnetization transfer preparation
pulse (MTon and MToff). Imaging for the RRMS group was performed
on a 1.5 T Phillips ACS II and the MT imaging consisted of a T1-FFE se-
quence (TR = 35 ms; TE = 10 ms; 40° ﬂip angle) with and without an
MT pre-pulse (on-resonance, binomial 1-2′-1 pulse; length 1200 µs).The SPMS group was a subset of a multicenter trial; subjects scanned
at sites that had MTR data from a normal control, required for normali-
zation, were used. The subjects used were scanned at 14 sites using
stock MTR sequences on each 1.5 T scanner. These were GE: 3D SPGR,
TR/TE 33–35/8–10 ms, 15° ﬂip + 8 ms Fermi pulse, 1200 Hz off- reso-
nance; Siemens: 3D FLASH, TR/TE 30/11 ms, 15° ﬂip + Gaussian
7.68 ms 250 Hz bandwidth, 1500 Hz offset, 500° effective ﬂip; Phillips:
3D T1-FFE, TR/TE 40/8 ms, 15° ﬂip + Gaussian 1200 Hz off-resonance.
Images for both groups had 1 × 1 × 3 mm voxels and whole brain
(60 slices) coverage.
Since the subjects in each group were scanned on different ma-
chines, enrolled in different studies and treated with different agents,
the two groups are not directly comparable. However, we examined
both separately, using the same methods, for evidence of repeated de-
myelination in both RRMS and SPMS.
MTon and MToff scans were coregistered and used to calculate an
MTR image using previously published techniques (Brown et al.,
2012). The MToff and other scans from each timepoint were also co-
registered to the T1w scan, and each T1w scan coregistered to the
T1w scan from the subject3s ﬁrst timepoint. The resulting set of trans-
forms allowed all images from each subject to be transformed into a
common space for analysis. All coregistration used a six degree of free-
dom (translation and rotation) linear transform (minctracc, McConnell
Brain Imaging Centre, Montreal) (Collins et al., 1994). MTR data from
different scanners were normalized and ΔMTR lesions were segmented
using the procedures in Brown et al. (2012). MTR normalization not
only allowed the pooling of data fromdifferent scanners, but also placed
theMTRmeasurements on a calibrated scale (Brown et al., 2011a, b). On
this scale, normal white matter has a value of 1.0 and normal gray mat-
ter 0.0. Thus, the difference between normal gray and white matter is
one unit.
Lesions were divided into de novo and repeat lesions. We assumed
that ΔMTR lesions appearing in previously NAWM represented a ﬁrst
round of demyelination, while those occurring in previously T2 hyper-
intense tissue were a subsequent, repeat round of demyelination. Indi-
vidual lesions that consisted of both a de novo and a repeat portion
were split into separate de novo and repeat lesions. This is consistent
with the histopathological observation that new demyelinating lesions
sometimes overlap shadow plaques (Prineas et al., 1993).
MTR timecourses for each lesion were constructed. Each timecourse
consisted of at least one MTR measurement at a minimum of 1 month
prior to lesion appearance (baseline), one measurement at the time
the lesion ﬁrst became evident (acute), and a number of follow-upmea-
surements at least 3 months after lesion appearance (follow-up).
Data were collected with the written informed consent of the sub-
jects involved and the approval of the institutional ethics review boards
of the collecting sites.
2.2. Analysis
MTR timecourses in lesions were modeled with a general linear
mixed model, according to the R formula:
MTR e acuteLesion þ postLesion þ lesionType
þ acuteLesion : lesionType þ postLesion : lesionType þ
ð1jsubject=timepoint=lesionÞ
where acuteLesion and postLesion are binary variables indicating
whether the measurement was from the acute or post-lesion phase
(both of these equal to zero indicates the baseline state) and lesionType
is a categorical variable equal to either “denovo” or “repeat”. A “:” indi-
cates an interaction between two variables. The last term, in brackets, is
a random effect of lesion nested within timepoint, within subject. This
term allows a lesion-speciﬁc random intercept and allows for correla-
tion among measurements in lesions in the same subject and at the
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datasets individually. During ﬁtting, observations were weighted by
the volume of the lesion. Since the measured MTR values are averages
over the voxels in each lesion,measurements from larger lesions are ex-
pected to have lower variance.
The overall ﬁt of each model was evaluated by comparing the log-
likelihoods of themodel and a null model using a χ2 test. If this was sig-
niﬁcant, f-tests were performed on the individual effects. Denominator
degrees of freedom for the f-tests were estimated using a Satterthwaite
approximation. R2 values were produced according to Nakagawa and
Schielzeth (2012), where the marginal R2 is the variance explained by
the ﬁxed effects alone, and the conditional R2 includes the contribution
of the random effects.
Image processing and statistical analysis were performed using
custom software written in Python (Python Software Foundation,
http://python.org) using the MINC tools (MINC tools, McConnell Brain
Imaging Centre, Montreal), the Scientiﬁc Python package (SciPy,
http://www.scipy.org), the RPy2 module (RPy2, http://rpy.sourceforge.
net) the R statistical package (R Team, 2010) and the lme4 (Bates
et al., 2011) andMixMod (Kuznetsova and Brockhoff, 2012) Rmodules.
Error bars and values are 95% conﬁdence intervals.3. Results
Both de novo and repeat lesions were successfully segmented, with
some examples shown in Fig. 1. Characteristic MTR timecourses were
obtained for both lesion types, from both groups (Fig. 2).
Table 1 contains descriptive statistics on the observed numbers and
volumes of de novo and repeat lesions, as well as the ratio between
them. De novo lesions were more common in the RRMS group, with a
median volume ratio of 3:1, but repeat lesions were slightly moreFig. 1. Examples of segmented de novo and repeat lesions. (A) shows large de novo (blue)
lesions and (B), a lower slice from the same subject, shows de novo and repeat (red) le-
sions in close proximity (arrow). (C) shows periventricular repeat lesions with no de
novo activity (arrow) and (D) shows a large repeat lesion.
Fig. 2.MTR timecourses in de novo (green) and repeat (blue)ΔMTR lesions from subjects
with RRMS (A) and SPMS (B). All lesions showed characteristic timecourseswithMTR de-
creasing at the time of lesion formation (time 0), then recovering partially afterward. Pre-
lesionMTR values in repeat lesions were similar, though lower, to post-recovery values in
denovo lesions. Heavy lines are predictions from themodelwhile light lines are individual
lesion timecourses. Shaded areas indicate 95% conﬁdence intervals.common in the SPMS group, with the de novo to repeat volume ratio
at 0.75:1.
Results of modeling the MTR timecourses are in Table 2, with the
timecourses themselves shown in Fig. 2. MTR decreased as lesions
formed (p b 0.0001) and increased on follow-up (p b 0.0001). The inter-
cepts of 0.45 in RRMS and 0.51 in SPMS suggest that MTR values were
low even in the NAWM preceding the formation of de novo lesions
(normal WM has a median value of 1.0). Follow-up MTR in de novo le-
sions in both groupswas lower than that at baseline, thoughhigher than
that at the acute timepoint, indicating partial recovery after the severe
drop at the time of lesion formation. The timecourses in repeat lesions
were very similar to those in de novo lesions, but with initial, pre-
lesion MTR values that were much lower than those in de novo lesions
(p b 0.0001). Average recovery of repeat lesionswas poorer than that of
de novo lesions, relative to their pre-lesion values, but this difference
was only signiﬁcant in the SPMS group (SPMS: p = 0.017; RRMS:
p= 0.068).
Note that the interactions listed in Table 2 indicate effects over and
above the main effects. For example, the non-signiﬁcant repeat le-
sions:follow-up effect in the RRMS group does not mean that repeat le-
sions in the RRMS group did not experience signiﬁcant MTR recovery.
Rather, these lesions did not experience a signiﬁcantly different amount
of recovery than did de novo lesions in the RRMS group.
Table 1
Descriptive statistics for lesions. STD is standard deviation and IQR is the inter-quartile ratio. De novo lesions were more common than repeat lesions in the RRMS group. The SPMS group
had fewer lesions and a more even ratio between de novo and repeat.
Lesion type Mean (STD) Median (IQR) Mean (STD)/year Median (IQR)/year
RRMS
Volume
(mm3)
T2 7374 (8729) 2315 (10,125)
de novo 181 (249) 42 (298) 2426 (3718) 710 (2838)
repeat 43 (72) 7.9 (50) 818 (1246) 252 (878)
Volume
(% of T2)
de novo 3.5 (5.7) 1.4 (3.8) 36 (56) 18 (34)
repeat 0.64 (1.0) 0.19 (0.94) 11 (16) 0.19 (0.94)
Count de novo 5.4 (6.6) 2.0 (9.0) 76 (114) 26 (88)
repeat 2.5 (3.8) 1.0 (3.0) 47 (72) 19 (42)
Volume ratio de novo : repeat 11 (22) 3.2 (9.3)
Count ratio 3.5 (5.7) 1.0 (4.0)
SPMS
Volume
(mm3)
T2 10,867 (10,292) 8201 (11,083)
de novo 79.8 (152) 26 (86) 411 (670) 189 (305)
repeat 95 (126) 49 (137) 544 (713) 251 (438)
Volume
(% of T2)
de novo 0.91 (2.1) 0.28 (0.77) 4.4 (8.8) 1.6 (3.9)
repeat 0.83 (1.1) 0.43 (1.1) 3.9 (6.3) 2.5 (3.5)
Count de novo 2.1 (2.6) 1.0 (3.0) 11 (12) 7.0 (8.6)
repeat 3.4 (4.0) 2.0 (5.0) 16 (17) 10 (17)
Volume ratio de novo : repeat 2.3 (4.9) 0.75 (1.6)
Count ratio 0.97 (1.9) 0.0 (1.0)
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Weobserved abnormally lowMTRvalues in normal appearingwhite
matter before the formation of a de novo lesion, consistent with studies
that have found evidence for diffuse damage in normal appearing tissue
inMS (De Stefano et al., 2002) and focal MTR decrease up to 2 years be-
fore lesion formation (Filippi et al., 1998; Goodkin et al., 1998; Pike et al.,
2000). We also measured signiﬁcant MTR recovery in both lesion types
in both groups, suggesting that remyelination is common in both forms
of MS. This observation is consistent with histopathological studies that
have found extensive remyelination (Patrikios et al., 2006). However,
mean MTR did not recover to pre-lesion levels, indicating that
remyelination was incomplete.
By examining novel ΔMTR lesions, we were able to identify MTR
changes not only in previously normal appearing tissue, but also in
existing T2 lesions. These repeat ΔMTR lesions were as common as deTable 2
Fixed effect estimates for the general linear mixedmodel of MTR in ΔMTR lesions for subjects w
subjects, χ2 = 5925 on 5 degrees of freedom, p b 0.0001. The ‘:’ in an effect denotes an interacti
interpretation but statistics apply to the effect estimates.
RRMS subjects, 120 timepoints, 1037 lesions, 9022 samples
χ2 = 5925; 5 DF; p b 0.0001; R2 marginal
Effect Prediction
(nMU)
Estimate
(nMU)
Intercept
(de novo lesions, baseline)
0.45 0.45
Acute −0.85 −1.29
Post-recovery 0.13 −0.31
Repeat lesions −0.29 −0.74
Repeat lesions: acute −1.31 0.28
Repeat lesions: follow-up −0.49 0.12
SPMS subjects, 221 timepoints, 1283 lesions, 5548 samples
χ2 = 4794; 5 DF; p b 0.0001; R2 marginal
Effect Prediction
(nMU)
Estimate
(nMU)
Intercept
(de novo lesions, baseline)
0.51 0.51
Acute −0.99 −1.51
Post-recovery −0.30 −0.81
Repeat lesions −0.74 −1.25
Repeat lesions: acute −1.82 0.42
Repeat lesions: follow-up −1.25 0.29novo lesions in SPMS, (Table 1), and exhibited MTR timecourses that
were remarkably similar in shape to those in de novo lesions, but with
baseline MTR values somewhat lower than follow-up values in de
novo lesions. This latter observation suggests that the repeat lesions
could be a subsequent round of demyelination in already damaged tis-
sue. The difference between follow-up de novo lesionMTR and baseline
repeat lesionMTR could be due to repeat lesions being amixture of sec-
ond, third or subsequent episodes, or a slow decline in MTR between
major inﬂammatory events. To address this, we reﬁt our models
with an additional term measuring the slope of the baseline MTR
timecourses. MTR in repeat lesions was not signiﬁcantly decreasing
prior to repeat lesion formation in either RRMSor SPMS; themeanbase-
lineMTR rose slightly, though not signiﬁcantly (RRMS: p=0.81, SPMS:
p= 0.14) in both groups.
Both de novo and repeat lesions experienced only partial MTR
recovery. This may be due to a combination of three mechanisms:ith RRMS. The model is signiﬁcant with 9022 samples from 120 subject-timepoints in 18
on. dDF is the estimated denominator degrees of freedom. Predictions are included to help
= 0.45; R2 conditional = 0.67
Std
Error
dDF f p
0.053
0.016 8072 4087 b0.0001
0.014 7985 146 b0.0001
0.025 5171 865 b0.0001
0.037 8119 20.6 b0.0001
0.030 8789 3.34 0.068
= 0.47; R2 conditional = 0.78
Std
Error
dDF f p
0.051
0.025 4295 4485 N0.0001
0.030 4410 700 N0.0001
0.029 5144 1612 N0.0001
0.033 4323 20.4 N0.0001
0.039 4655 5.70 0.017
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by remyelination are thinner (Bruck et al., 2003; Perier and Gregoire,
1965; Prineas and Connell, 1979; Rodriguez and Scheithauer, 1994);
(2) apparently chronically demyelinated axons are commonly observed
in lesions, suggesting that some axons may remain viable even without
remyelination (Craner et al., 2003); and (3) acute axonal damage, includ-
ing transection, is common inMS lesions (Kornek et al., 2000; Trapp et al.,
1998) and quantitative histopathology reveals that 30% (Schmierer et al.,
2004, 2007) to 60% (Mews et al., 1998) of axons may be lost in
remyelinated lesions. MTR imaging is limited in that it cannot differenti-
ate between these processes. While remyelination-promoting therapies
in development are generally aimed at stimulating remyelination of
axons that would otherwise remain bare, the results of Schmierer et al.
(2004, 2007) and Mews et al. (1998) suggest that axonal loss is a major
mechanism of incomplete lesion recovery. However, as remyelination
protects axons against delayed axonal degeneration (Kornek et al.,
2000), improved remyelination will also help preserve axons.
Ideally, repeated episodes of demyelination and remyelination
would be studied by direct observation of these events in the same le-
sions. However, if remyelinated tissue is not much more likely to expe-
rience subsequent demyelination, as has been observed by our group
and others, a second demyelinating episode in a given lesion may not
occur for years. Therefore, direct observation of a statistically meaning-
ful sample of repeated episodes of demyelinationmay require a longitu-
dinal imaging study spanningmany years. Our own data was limited to
less than 2 years of scanning in both groups, requiring the assumption
that a T2 lesion indicated a previous demyelinating episode.
Our results support the hypothesis that focal white matter lesions
may undergo multiple demyelination and remyelination episodes. We
observed MTR to recover to stable values, consistent with the ﬁndings
of others (Brown et al., 2012; Chen et al., 2008; Richert et al., 2001), sug-
gesting that remyelination is not a transient phenomenon. This suggests
amodel inwhich demyelination in lesions occursmostly during acute in-
ﬂammatory episodes, and is routinely followed by partial remyelination;
the severe lesions containing little or nomyelin seen at autopsywould be
the end result of a series of inﬂammatory episodes with incremental net
myelin loss resulting from each. This model of lesion development may
have implications for treatment: with the availability of drugs that effec-
tively control inﬂammation and reduce the formation of new lesions,
there is growing interest in neuroprotective and remyelination promot-
ing agents. Imaging of not only the ﬁrst cycle of demyelination and
remyelination but also subsequent episodes may help determine the
mechanisms behind incomplete remyelination and identify possible
treatment targets. Additionally, the relative abundance of repeat lesions
in SPMS may mean that focal inﬂammatory activity in this phase of the
disease has been underappreciated. In our SPMS group more than half
of the ΔMTR lesions were repeat lesions, which would not be captured
by measurements of new T2 lesions or T2 lesion volume.
We used a new technique involving analysis of MTR timecourses in
ΔMTR lesions to examine demyelination and remyelination inMS. Stan-
dard T2 lesions have low speciﬁcity and, since T2 hyperintensity often
persists, cannot reliably identify repeated episodes of demyelination in
the same tissue. ΔMTR lesions are segmented from semi-quantitative
MTR images so they are more speciﬁc to changes in myelin and
can identify repeated demyelination. This allowed us to test the
longstanding hypothesis that the completely demyelinated MS lesions
seen at autopsy are not the result of a complete failure of remyelination,
but rather are the end product of a series of demyelination events
followed by robust, but incomplete, remyelination. Our results support
this hypothesis and demonstrate that repeat demyelination is a com-
mon, and likely important, process in MS.
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